A citation-based method for searching scientific literature

Marc S Sabatine, Robert P Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D Wiviott, Sabina A Murphy, Julia F Kuder, Huei Wang, Thomas Liu, Scott M Wasserman, Peter S Sever, Terje R Pedersen. N Engl J Med 2017
Times Cited: 2301







List of co-cited articles
671 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington,[...]. N Engl J Med 2018
71

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
39

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference,[...]. Eur Heart J 2020
32

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
C Baigent, L Blackwell, J Emberson, L E Holland, C Reith, N Bhala, R Peto, E H Barnes, A Keech, J Simes,[...]. Lancet 2010
23

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Deepak L Bhatt, P Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. N Engl J Med 2019
21

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.
Sotirios Tsimikas, Ewa Karwatowska-Prokopczuk, Ioanna Gouni-Berthold, Jean-Claude Tardif, Seth J Baum, Elizabeth Steinhagen-Thiessen, Michael D Shapiro, Erik S Stroes, Patrick M Moriarty, Børge G Nordestgaard,[...]. N Engl J Med 2020
196
15

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Paul M Ridker, Brendan M Everett, Tom Thuren, Jean G MacFadyen, William H Chang, Christie Ballantyne, Francisco Fonseca, Jose Nicolau, Wolfgang Koenig, Stefan D Anker,[...]. N Engl J Med 2017
14

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
Brian A Ference, Henry N Ginsberg, Ian Graham, Kausik K Ray, Chris J Packard, Eric Bruckert, Robert A Hegele, Ronald M Krauss, Frederick J Raal, Heribert Schunkert,[...]. Eur Heart J 2017
13

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Kausik K Ray, R Scott Wright, David Kallend, Wolfgang Koenig, Lawrence A Leiter, Frederick J Raal, Jenna A Bisch, Tara Richardson, Mark Jaros, Peter L J Wijngaard,[...]. N Engl J Med 2020
186
12

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Stephen J Nicholls, Rishi Puri, Todd Anderson, Christie M Ballantyne, Leslie Cho, John J P Kastelein, Wolfgang Koenig, Ransi Somaratne, Helina Kassahun, Jingyuan Yang,[...]. JAMA 2016
488
11

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Jennifer G Robinson, Michel Farnier, Michel Krempf, Jean Bergeron, Gérald Luc, Maurizio Averna, Erik S Stroes, Gisle Langslet, Frederick J Raal, Mahfouz El Shahawy,[...]. N Engl J Med 2015
11

Interpretation of the evidence for the efficacy and safety of statin therapy.
Rory Collins, Christina Reith, Jonathan Emberson, Jane Armitage, Colin Baigent, Lisa Blackwell, Roger Blumenthal, John Danesh, George Davey Smith, David DeMets,[...]. Lancet 2016
862
11

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
Paul M Ridker, James Revkin, Pierre Amarenco, Robert Brunell, Madelyn Curto, Fernando Civeira, Marcus Flather, Robert J Glynn, Jean Gregoire, J Wouter Jukema,[...]. N Engl J Med 2017
363
11

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Scott M Grundy, Neil J Stone, Alison L Bailey, Craig Beam, Kim K Birtcher, Roger S Blumenthal, Lynne T Braun, Sarah de Ferranti, Joseph Faiella-Tommasino, Daniel E Forman,[...]. J Am Coll Cardiol 2019
780
10

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
Kausik K Ray, Harold E Bays, Alberico L Catapano, Narendra D Lalwani, LeAnne T Bloedon, Lulu R Sterling, Paula L Robinson, Christie M Ballantyne. N Engl J Med 2019
201
10

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
10

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M Ridker, Eleanor Danielson, Francisco A H Fonseca, Jacques Genest, Antonio M Gotto, John J P Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Jean G MacFadyen,[...]. N Engl J Med 2008
10

Evinacumab for Homozygous Familial Hypercholesterolemia.
Frederick J Raal, Robert S Rosenson, Laurens F Reeskamp, G Kees Hovingh, John J P Kastelein, Paolo Rubba, Shazia Ali, Poulabi Banerjee, Kuo-Chen Chan, Daniel A Gipe,[...]. N Engl J Med 2020
111
10

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Robert P Giugliano, Terje R Pedersen, Jeong-Gun Park, Gaetano M De Ferrari, Zbigniew A Gaciong, Richard Ceska, Kalman Toth, Ioanna Gouni-Berthold, Jose Lopez-Miranda, François Schiele,[...]. Lancet 2017
289
9

Cognitive Function in a Randomized Trial of Evolocumab.
Robert P Giugliano, François Mach, Kenton Zavitz, Christopher Kurtz, Kyungah Im, Estella Kanevsky, Jingjing Schneider, Huei Wang, Anthony Keech, Terje R Pedersen,[...]. N Engl J Med 2017
225
9

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
9

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
Frederick J Raal, David Kallend, Kausik K Ray, Traci Turner, Wolfgang Koenig, R Scott Wright, Peter L J Wijngaard, Danielle Curcio, Mark J Jaros, Lawrence A Leiter,[...]. N Engl J Med 2020
129
9

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
Mark J Graham, Richard G Lee, Teresa A Brandt, Li-Jung Tai, Wuxia Fu, Raechel Peralta, Rosie Yu, Eunju Hurh, Erika Paz, Bradley W McEvoy,[...]. N Engl J Med 2017
295
9

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
Marc S Sabatine, Robert P Giugliano, Stephen D Wiviott, Frederick J Raal, Dirk J Blom, Jennifer Robinson, Christie M Ballantyne, Ransi Somaratne, Jason Legg, Scott M Wasserman,[...]. N Engl J Med 2015
9

Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Christopher P Cannon, Eugene Braunwald, Carolyn H McCabe, Daniel J Rader, Jean L Rouleau, Rene Belder, Steven V Joyal, Karen A Hill, Marc A Pfeffer, Allan M Skene. N Engl J Med 2004
8

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.
Veronica J Alexander, Shuting Xia, Eunju Hurh, Steven G Hughes, Louis O'Dea, Richard S Geary, Joseph L Witztum, Sotirios Tsimikas. Eur Heart J 2019
70
11

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
Michelle L O'Donoghue, Sergio Fazio, Robert P Giugliano, Erik S G Stroes, Estella Kanevsky, Ioanna Gouni-Berthold, KyungAh Im, Armando Lira Pineda, Scott M Wasserman, Richard Češka,[...]. Circulation 2019
233
8

Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
Jean-Claude Tardif, Simon Kouz, David D Waters, Olivier F Bertrand, Rafael Diaz, Aldo P Maggioni, Fausto J Pinto, Reda Ibrahim, Habib Gamra, Ghassan S Kiwan,[...]. N Engl J Med 2019
684
8

Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
Kenichi Tsujita, Seigo Sugiyama, Hitoshi Sumida, Hideki Shimomura, Takuro Yamashita, Kenshi Yamanaga, Naohiro Komura, Kenji Sakamoto, Hideki Oka, Koichi Nakao,[...]. J Am Coll Cardiol 2015
223
7

Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Robert P Giugliano, Christopher P Cannon, Michael A Blazing, José C Nicolau, Ramón Corbalán, Jindřich Špinar, Jeong-Gun Park, Jennifer A White, Erin A Bohula, Eugene Braunwald. Circulation 2018
155
7

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
John W Eikelboom, Stuart J Connolly, Jackie Bosch, Gilles R Dagenais, Robert G Hart, Olga Shestakovska, Rafael Diaz, Marco Alings, Eva M Lonn, Sonia S Anand,[...]. N Engl J Med 2017
970
7

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
Marc P Bonaca, Patrice Nault, Robert P Giugliano, Anthony C Keech, Armando Lira Pineda, Estella Kanevsky, Julia Kuder, Sabina A Murphy, J Wouter Jukema, Basil S Lewis,[...]. Circulation 2018
314
7

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
Marianne Abifadel, Mathilde Varret, Jean-Pierre Rabès, Delphine Allard, Khadija Ouguerram, Martine Devillers, Corinne Cruaud, Suzanne Benjannet, Louise Wickham, Danièle Erlich,[...]. Nat Genet 2003
7

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
Marc S Sabatine, Lawrence A Leiter, Stephen D Wiviott, Robert P Giugliano, Prakash Deedwania, Gaetano M De Ferrari, Sabina A Murphy, Julia F Kuder, Ioanna Gouni-Berthold, Basil S Lewis,[...]. Lancet Diabetes Endocrinol 2017
279
7

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.
Brian A Ference, Jennifer G Robinson, Robert D Brook, Alberico L Catapano, M John Chapman, David R Neff, Szilard Voros, Robert P Giugliano, George Davey Smith, Sergio Fazio,[...]. N Engl J Med 2016
377
7

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
Vera A Bittner, Michael Szarek, Philip E Aylward, Deepak L Bhatt, Rafael Diaz, Jay M Edelberg, Zlatko Fras, Shaun G Goodman, Sigrun Halvorsen, Corinne Hanotin,[...]. J Am Coll Cardiol 2020
113
7


Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Nicholas J Viney, Julian C van Capelleveen, Richard S Geary, Shuting Xia, Joseph A Tami, Rosie Z Yu, Santica M Marcovina, Steven G Hughes, Mark J Graham, Rosanne M Crooke,[...]. Lancet 2016
383
7

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.
Joseph L Witztum, Daniel Gaudet, Steven D Freedman, Veronica J Alexander, Andres Digenio, Karren R Williams, Qingqing Yang, Steven G Hughes, Richard S Geary, Marcello Arca,[...]. N Engl J Med 2019
144
7

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.
Kevin Fitzgerald, Suellen White, Anna Borodovsky, Brian R Bettencourt, Andrew Strahs, Valerie Clausen, Peter Wijngaard, Jay D Horton, Jorg Taubel, Ashley Brooks,[...]. N Engl J Med 2017
330
7

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
C Baigent, A Keech, P M Kearney, L Blackwell, G Buck, C Pollicino, A Kirby, T Sourjina, R Peto, R Collins,[...]. Lancet 2005
7

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.
Erik S Stroes, Paul D Thompson, Alberto Corsini, Georgirene D Vladutiu, Frederick J Raal, Kausik K Ray, Michael Roden, Evan Stein, Lale Tokgözoğlu, Børge G Nordestgaard,[...]. Eur Heart J 2015
681
7

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.
Jordan Fulcher, Rachel O'Connell, Merryn Voysey, Jonathan Emberson, Lisa Blackwell, Borislava Mihaylova, John Simes, Rory Collins, Adrienne Kirby, Helen Colhoun,[...]. Lancet 2015
678
6

Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association.
Emelia J Benjamin, Salim S Virani, Clifton W Callaway, Alanna M Chamberlain, Alexander R Chang, Susan Cheng, Stephanie E Chiuve, Mary Cushman, Francesca N Delling, Rajat Deo,[...]. Circulation 2018
6

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.
Louise Bowman, Jemma C Hopewell, Fang Chen, Karl Wallendszus, William Stevens, Rory Collins, Stephen D Wiviott, Christopher P Cannon, Eugene Braunwald, Emily Sammons,[...]. N Engl J Med 2017
480
6

Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.
Ulrich Laufs, Maciej Banach, G B John Mancini, Daniel Gaudet, LeAnne T Bloedon, Lulu Ren Sterling, Stephanie Kelly, Erik S G Stroes. J Am Heart Assoc 2019
115
6

Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
Anne C Goldberg, Lawrence A Leiter, Erik S G Stroes, Seth J Baum, Jeffrey C Hanselman, LeAnne T Bloedon, Narendra D Lalwani, Pragna M Patel, Xin Zhao, P Barton Duell. JAMA 2019
122
6

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Scott M Grundy, Neil J Stone, Alison L Bailey, Craig Beam, Kim K Birtcher, Roger S Blumenthal, Lynne T Braun, Sarah de Ferranti, Joseph Faiella-Tommasino, Daniel E Forman,[...]. Circulation 2019
771
6

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
6

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.